Stock Scorecard
Stock Summary for NovoCure Ltd (NVCR) - $16.86 as of 11/20/2024 8:30:54 PM EST
Total Score
8 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for NVCR
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NVCR
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NVCR
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for NVCR
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for NVCR (32 out of 90)
Stock Price Rating (Max of 10) | 6 |
Historical Stock Price Rating (Max of 10) | 10 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 3 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 3 |
Analyst Strong Buy Ratings (Max of 5) | 3 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 6 |
Price to Earnings (Max of 10) | 0 |
Latest News for for NVCR
Financial Details for NVCR
Company Overview |
|
---|---|
Ticker | NVCR |
Company Name | NovoCure Ltd |
Country | USA |
Description | NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey. |
Sector Name | LIFE SCIENCES |
Industry Name | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 16.86 |
Price 4 Years Ago | 173.04 |
Last Day Price Updated | 11/20/2024 8:30:54 PM EST |
Last Day Volume | 673,938 |
Average Daily Volume | 1,216,529 |
52-Week High | 24.73 |
52-Week Low | 11.29 |
Last Price to 52 Week Low | 49.34% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 52.46 |
Sector PE | 40.32 |
5-Year Average PE | -18.31 |
Free Cash Flow Ratio | 1.90 |
Industry Free Cash Flow Ratio | 35.05 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 1.49 |
Total Cash Per Share | 8.87 |
Book Value Per Share Most Recent Quarter | 3.34 |
Price to Book Ratio | 4.83 |
Industry Price to Book Ratio | 5.44 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 3.02 |
Industry Price to Sales Ratio Twelve Trailing Months | 13.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 2 |
Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
Total Shares Outstanding | 108,201,000 |
Market Capitalization | 1,824,268,860 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | -6.00% |
Annual Earnings Growth | -123.75% |
Reported EPS 12 Trailing Months | -1.39 |
Reported EPS Past Year | -0.95 |
Reported EPS Prior Year | -1.95 |
Net Income Twelve Trailing Months | -149,784,000 |
Net Income Past Year | -207,043,000 |
Net Income Prior Year | -92,534,000 |
Quarterly Revenue Growth YOY | 21.80% |
5-Year Revenue Growth | 15.47% |
Operating Margin Twelve Trailing Months | -0.21 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 959,898,000 |
Total Cash Past Year | 910,616,000 |
Total Cash Prior Year | 969,425,000 |
Net Cash Position Most Recent Quarter | 305,416,000 |
Net Cash Position Past Year | 341,794,000 |
Long Term Debt Past Year | 568,822,000 |
Long Term Debt Prior Year | 565,509,000 |
Total Debt Most Recent Quarter | 654,482,000 |
Equity to Debt Ratio Past Year | 0.39 |
Equity to Debt Ratio Most Recent Quarter | 0.36 |
Total Stockholder Equity Past Year | 362,496,000 |
Total Stockholder Equity Prior Year | 441,170,000 |
Total Stockholder Equity Most Recent Quarter | 360,781,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -78,210,000 |
Free Cash Flow Per Share Twelve Trailing Months | -0.72 |
Free Cash Flow Past Year | -100,429,000 |
Free Cash Flow Prior Year | 9,430,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.36 |
MACD Signal | 0.19 |
20-Day Bollinger Lower Band | 14.71 |
20-Day Bollinger Middle Band | 17.50 |
20-Day Bollinger Upper Band | 20.29 |
Beta | 0.70 |
RSI | 55.12 |
50-Day SMA | 16.36 |
150-Day SMA | 47.33 |
200-Day SMA | 73.11 |
System |
|
Modified | 11/19/2024 8:37:27 AM EST |